title: Changes in body composition after spasticity treatment with intrathecal baclofen.
abstract: OBJECTIVE
  To assess changes in body composition, body weight and resting metabolic rate in patients who received intrathecal baclofen therapy for spasticity.
  
  
  METHODS
  Prospective, longitudinal, quasi-experimental, with a pre/post design.
  
  
  METHODS
  Twelve patients with spasticity, fulfilling study criteria, and due for pump implantation for intrathecal baclofen therapy, completed the study.
  
  
  METHODS
  Data were obtained before, 6 months and 12 months after commencement of intrathecal baclofen therapy as regards body composition (by skinfold calliper), body weight, and resting metabolic rate (by resting oxygen consumption). Spasticity was assessed according to the Modified Ashworth Scale (MAS) and Penn Spasm Frequency Scale (PSFS).
  
  
  RESULTS
  A reduction in spasticity according to MAS occurred. Mean fat body mass increased and mean lean body mass decreased. Mean body weight showed a non-significant increase and resting metabolic rate a non-significant decrease.
  
  
  CONCLUSIONS
  This explorative study indicates that unfavourable changes in body composition might occur after intrathecal baclofen therapy. Since obesity and increased fat body mass contribute to an increased cardiovascular risk, these findings may indicate a need for initiation of countermeasures, e.g. increased physical activity and/or dietary measures, in conjunction with intrathecal baclofen therapy. Further studies, including larger study samples and control groups, are needed to corroborate these findings.
authors.forename: Olle
authors.initials: O
authors.lastname: Skogberg
authors.forename: Kersti
authors.initials: K
authors.lastname: Samuelsson
authors.forename: Per
authors.initials: P
authors.lastname: Ertzgaard
authors.affiliation: Clinical Department of Rehabilitation Medicine and Department of Medicine and Health Sciences, Linköping University, SE-585 85 Linköping, Sweden. E-mail: richard.levi@regionostergotland.se.
authors.forename: Richard
authors.initials: R
authors.lastname: Levi
mesh_terms: D000328:Adult; D000368:Aged; D001418:Baclofen / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001823:Body Composition / Q000502:physiology*; D001835:Body Weight / Q000502:physiology*; D005260:Female; D006801:Humans; D007278:Injections, Spinal / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009125:Muscle Relaxants, Central / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D009128:Muscle Spasticity / Q000188:drug therapy*; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D009125:Muscle Relaxants, Central; D001418:Baclofen